In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 records · Data version 308560
Swipe sideways to see every peptide.
| Peptide | |||
|---|---|---|---|
| Identity | |||
| Kind | Small molecule | Small molecule | |
| Area | Longevity and mitochondria | Longevity and mitochondria | |
| Evidence | |||
| Amount of evidence | 42 | 1,513 (plus 2 on natural levels, listed separately) | |
| Evidence level | Results from animal studies only | Has results from studies in people | |
| Safety | |||
| Safety results | 1 (0 in people) | 64 (35 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | None registered | 19 · 8 active14 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Preclinical research only. No clinical trial phase found. The FDA, the EMA and the other sources we use show no approval (as of 13 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | SLU-PP-332 | NMN (nicotinamide mononucleotide) |
|---|---|---|
| Receptor activity and mechanismPharmacology | 1138 | 2138 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 21 Oct 2026).
| Mitochondrial functionMusculoskeletal | 624 | 143104381 |
|---|
| Inflammation markersKidney and urinary | 22 | 131391361 |
|---|
| Adverse eventsWhole body | 11 | 4328132 |
|---|
| Exercise and physical functionMusculoskeletal | 44 | 33258 |
|---|
| PharmacokineticsPharmacology | 11 | 32248 |
|---|
| Aging markersMusculoskeletal | 11 | 5723322 |
|---|
| Heart functionCardiovascular | 33 | 561523 |
|---|
| Kidney functionKidney and urinary | 22 | 454365 |
|---|
| Glycemic controlMetabolic and weight | 22 | 295213 |
|---|
| Body weightMetabolic and weight | 33 | 20119 |
|---|
| Cell viability and deathMusculoskeletal | 11 | 22616 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
No registered trial that tests SLU-PP-332 found in ClinicalTrials.gov.
Top 3 of 19 trials, ranked by phase, then posted results and enrollment: 1 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)
First Affiliated Hospital, Sun Yat-Sen University20 participants1 Jun 2021 to est. 31 Jul 2022
Hypertension
Christopher Kai Shun Leung138 participants19 May 2025 to est. 31 Dec 2026
Glaucoma
Zhejiang Chinese Medical University22 participants1 May 2024 to 6 Apr 2025
Binge Drinking · Liver Injury · Nutritional Supplementation · Hepatic Steatosis
14 more mention it but do not test it. They only measure it or name it in their text.